Floatz logo

MP0533

Newly Diagnosed

Molecular Partners AGPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Newly Diagnosed cohort.

Asset / SponsorPhaseRating
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
Bortezomib
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB
Daunorubicin
Fujian Medical University Union Hospital
Phase 4B

View all 34 →

Same molecule, other indications

MP0533 is also rated in:

myeloid neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
acute diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →